Kymera Therapeutics (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.
The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.
Analysts polled by Capital IQ expected a $0.84 loss.
Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.
Analysts surveyed by Capital IQ expected $10.3 million.
In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.
Price: 46.97, Change: -0.70, Percent Change: -1.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.